APA aipamena

Sutherland, J. E., Hettinger, J. L., Chan, A., Gilbert, J., Warner, G. L., & Davis, W. P. (2020). Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. Nucleic Acid Ther.

Chicago Style aipamena

Sutherland, Jessica E., Julia L. Hettinger, Amy Chan, Jason Gilbert, Garvin L. Warner, and Wendell P. Davis. "Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis." Nucleic Acid Ther 2020.

MLA aipamena

Sutherland, Jessica E., et al. "Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis." Nucleic Acid Ther 2020.